In a subset of patients with diabetes taking metformin from the ALTTO trial, a phase III adjuvant trial for patients with HER2+ breast cancer receiving trastuzumab, lapatinib, or the combination, a beneficial effect of metformin was observed. This evidence concerns the gene ERBB2 and breast carcinoma.